Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G/A

Scholar Rock Holding Corporation

SRRKNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 16, 2026Accepted Nov 16, 2026, 10:00 AM ESTFiling CIK 1727196Accession 0000080255-26-000708
Share

Structured filing — SCHEDULE 13G/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
SCHOLAR ROCK HOLDING CORP
Company CIK
0001727196
Street
301 BINNEY STREET
Street (continued)
3RD FLOOR
City
CAMBRIDGE
State / country code
MA
Postal code
02142

Statement details

Amendment number
9
Security class
COMMON STOCK
Event date
09/30/2026
Rule designation
Rule 13d-1(b)

Reporting person 1

Name
T. Rowe Price Associates, Inc.
Citizenship / organization
MD
Reporting person type
IA
Aggregate amount owned
5,865,988
Percent of class
4.8
Sole voting power
5,861,872
Shared voting power
0
Sole dispositive power
5,865,988
Shared dispositive power
0
Aggregate excludes certain shares
N

Item 1

Issuer

SCHOLAR ROCK HOLDING CORP

Principal executive office address

301 BINNEY STREET, 3RD FLOOR, CAMBRIDGE, MA, 02142

Item 2

Citizenship

Maryland

Filing person

T. Rowe Price Associates, Inc.

Principal business or residence address

1307 Point Street, Baltimore, MD 21231

Item 3

Not applicable indication

N

Type of filing person

IA

Item 4

Percent of class

4.8

Amount beneficially owned

5865988

Sole voting power

5861872

Shared voting power

0

Sole dispositive power

5865988

Shared dispositive power

0

Item 5

Not applicable indication

N

Ownership of 5% or less

Y

Item 6

Not applicable indication

Y

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Signature 1

Reporting person
T. Rowe Price Associates, Inc.
Signed
Ellen York
Title
Vice President
Date
11/16/2026

Company context

Scholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need. Following FDA approval in September 2026, Scholar Rock is commercializing ISEMBLYD (apitegromab-mstn) in the U.S. for people living with SMA who are 2 years of age and older and currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. The Company plans to expand access to ISEMBYLD globally, in up to 50 countries worldwide, subject to regulatory approvals.

Current securities

Recent company filings

  1. SCHEDULE 13G/A - filed by WELLINGTON MANAGEMENT GROUP LLP regarding Scholar Rock Holding CorpNov 16, 2026
  2. 10-Q filingNov 10, 2026
  3. Entry into a Material Definitive Agreement · Results of Operations and Financial Condition · Regulation FD DisclosureNov 10, 2026
  4. 4 filingOct 27, 2026
  5. 4 filingSep 23, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.